Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 [ Read More ]
Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 [ Read More ]
Results of the Ni-HIGH study showed that the combination of nivolumab plus trastuzumab and either S-1 or capecitabine plus oxaliplatin was tolerable and showed promising antitumor activity in chemotherapy-naïve patients with HER2-positive advanced gastric cancer.
Findings of the phase 2 study of FOLFOX plus nab-paclitaxel indicate that the anthracycline-based triplet regimen was associated with a high response rate and expected toxicities in patients with metastatic or advanced unresectable gastric/gastroesophageal junction adenocarcinoma.
Results from the GERCOR NEONIPIGA phase 2 study indicated that neoadjuvant therapy with nivolumab and ipilimumab was feasible and was associated with a high pathologic complete response rate in patients with microsatellite instability-high/mismatch repair deficient resectable esophagogastric junction and gastric adenocarcinoma.
Updated results from the DESTINY-Gastric01 study indicate that trastuzumab deruxtecan therapy continued to demonstrate overall survival benefit compared with chemotherapy, accompanied by a manageable safety profile, in previously treated HER2-positive advanced gastric cancer or gastroesophageal junction cancer.
Results from the multicohort phase 1/2 KRYSTAL-1 study indicated that adagrasib monotherapy was well-tolerated and demonstrated encouraging clinical activity in pretreated patients with gastrointestinal tumors harboring a KRAS G12C mutation.
Updated results of the CheckMate 649 study indicated that nivolumab + chemotherapy continued to demonstrate clinically meaningful improvement in efficacy with 24-month follow-up, with no emergence of new safety issues.
